Javara Announces Board Expansion

Javara Expands Board with Industry Luminaries Patricia Leuchten and Tom Pike; Appoints Jeff Kasher, PhD, as Chair

[Winston-Salem, NC — October 2025] Javara, a leading Integrated Research Organization (IRO) dedicated to improving clinical trial access and advancing innovation in healthcare, has announced the appointment of Thomas Pike and Patricia Leuchten to its Board of Directors, alongside the elevation of Jeff Kasher, PhD, to Board Chair. They join industry veterans and current Board Directors Todd Johnson and Josef von Rickenbach.

Additional changes to the Board include the appointment of Walker Carpenter of General Atlantic to Board Director, and Brett Zbar, MD, who will now serve as Board Observer.

Collectively, these accomplished leaders bring deep expertise in clinical trial networks, healthcare system partnerships, and operational excellence. Their combined experience will play a pivotal role in accelerating Javara’s mission to become the most trusted partner for patients, health organizations, and pharmaceutical and CROs alike.

Thomas Pike

Recognized for guiding Quintiles (now IQVIA) through its IPO and global transformation, and for his leadership as Chairman & CEO of Fortrea (Nasdaq: FTRE), Pike will strengthen Javara’s ability to expand pharma and CRO collaborations and scale point-of-care clinical trials across health system networks.

Patricia Leuchten

Founder & CEO of Diligent Pharma and previously founder of The Avoca Group, Leuchten brings unmatched expertise in clinical quality, risk mitigation, and vendor collaboration. Her addition reinforces Javara’s commitment to operational excellence and regulatory compliance, critical differentiators for sponsors seeking more reliable and efficient clinical trial execution.

Walker Carpenter

Vice President at General Atlantic, Carpenter brings extensive experience in healthcare investing and strategic growth. He will support the continued expansion of Javara’s integrated research model to maximize the organization’s innovation and impact as a leading U.S. site network.

Jeff Kasher, PhD

A long-standing advocate for patient-centric research and former pharma R&D executive, Kasher now assumes the role of Board Chair. As featured in Modern Healthcare, he will guide Javara’s growth strategy to ensure diverse patient access, accelerated enrollment, and richer real-world data across its expanding healthcare research network.

From the Founder

“Welcoming Patty Leuchten, Tom Pike, and Walker Carpenter, and appointing Jeff Kasher as Board Chair, comes at a key juncture as Javara leads the next era of integrated clinical research,” said Jennifer Byrne, Founder & CEO of Javara. “We are profoundly grateful for these tremendously talented and mission-driven individuals and the exceptional contributions each will bring to the company. I believe they will challenge our management team to accelerate growth and leverage the full value proposition we bring to both our healthcare and industry partners.”

About Javara

A leading Integrated Research Organization (IRO), Javara partners with healthcare systems and specialty practices to expand access to clinical trials at the point of care, connecting patients to research through physicians they already trust, in communities they already love.

Javara’s model unlocks access to broader, more diverse populations, driving faster enrollment, stronger retention, and richer data. With a site network powered by centralized resources and streamlined operations, Javara accelerates study start-up and reduces friction across the research lifecycle.

Research, integrated. Healthcare, elevated. For more information, visit javararesearch.com and follow the company on LinkedIn.

.